

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173783 A3

(51) International Patent Classification:

A61K 31/712 (2006.01) C12N 15/113 (2010.01)
A61K 31/7125 (2006.01) A61P 25/16 (2006.01)
C07H 21/04 (2006.01)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2024/016133

(88) Date of publication of the international search report:

07 November 2024 (07.11.2024)

(22) International Filing Date:

16 February 2024 (16.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/485,850 17 February 2023 (17.02.2023) US
63/587,714 03 October 2023 (03.10.2023) US

(71) Applicant: IONIS PHARMACEUTICALS, INC.

[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: OESTERGAARD, Michael; c/o Ionis Pharma-

ceuticals, Inc., 2855 Gazelle Ct., Carlsbad, CA 92010 (US).
SETH, Punit, P.; 6773 Mallee St., Carlsbad, CA 92011
(US).

(74) Agent: SCARR, Rebecca, B. et al.; McNeill Baur PLLC,

125 Cambridge Park Dr, Suite 301, Cambridge, MA 02140
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ALLELE-SELECTIVE COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN EXPRESSION

(57) Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use for selectively reducing the amount or activity of HTT RNA comprising SNP rs7685686 in a cell or subject, and in certain instances reducing the amount of mutant HTT protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of Huntington's disease.

WO 2024/173783 A3